Literature DB >> 27393300

Comment on: "One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients" by Boschetti et al.

Lorenzo Curtò1, Cesare de Gregorio2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27393300     DOI： 10.1007/s12020-016-1024-4

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  3 in total

1.  Systemic hypertension counteracts potential benefits of growth hormone replacement therapy on left ventricular remodeling in adults with growth hormone deficiency.

Authors:  C de Gregorio; L Curtò; F Marini; G Andò; O Trio; F Trimarchi; S Coglitore; S Cannavò
Journal:  J Endocrinol Invest       Date:  2012-10-15       Impact factor: 4.256

2.  Cardiovascular outcomes and conventional risk factors in non-diabetic adult patients with GH deficiency: A long-term retrospective cohort study.

Authors:  Cesare de Gregorio; Giuseppe Andò; Salvatore Cannavò; Oana Ruxandra Cotta; Olimpia Trio; Maurizio Cusmà Piccione; Francesco Trimarchi; Lorenzo Curtò
Journal:  Eur J Intern Med       Date:  2015-11-06       Impact factor: 4.487

3.  One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients.

Authors:  Mara Boschetti; Sergio Agosti; Valeria Albanese; Laura Casalino; Claudia Teti; Gian Paolo Bezante; Claudio Brunelli; Manuela Albertelli; Diego Ferone
Journal:  Endocrine       Date:  2016-04-13       Impact factor: 3.633
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.